The F.D.A. suspends use of a Glaxo antibody drug in the U.S. as an Omicron subvariant spreads.. Coronavirus (2019-nCoV), Coronavirus Omicron Variant, Drugs (Pharmaceuticals), Food and Drug Administration, GlaxoSmithKline PLC